Value proposition

We fund the Trials Acceleration Programme (TAP) which delivers & connects patients to blood cancer clinical trials.

One person is diagnosed with blood cancer every 14 minutes. Help us to help save more lives and eradicate all forms of blood cancer within the next 15 years.

Founded in 2003 by Professor Charlie Craddock CBE and patients Graham Silk and Michael Woolley, Cure Leukaemia helps to bring pioneering drug and transplant treatments to blood cancer patients across the United Kingdom. The charity has committed £3m from 2020-22 to fund the Trials Acceleration Programme (TAP) comprising a network of 12 blood cancer centres across the UK.

Cure Leukaemia fund specialist research nurses at these centres allowing clinical trials of pioneering and potentially life-saving treatments for blood cancer to run giving patients from a catchment area of over 20m access to these new drugs. Cure Leukaemia also funds the TAP’s Hub based at the internationally renowned Centre for Clinical Haematology at Queen Elizabeth Hospital in Birmingham to co-ordinate these pioneering trials.

Without the expert research nurses to ensure patients are constantly monitored and cared for; these trials would not run, and patients would miss the opportunity to access potentially life-saving therapies. The aim of Cure Leukaemia is to raise money to fund more research nurses and provide world-class treatment for its patients. Only by funding more nurses in more hospitals, can more blood cancer patients benefit from access to potentially life-saving treatment.

In 2017 Cure Leukaemia raised an additional £1m to help fully fund the expansion of the Centre for Clinical Haematology (CCH). The transformational £3.4m project doubled its capacity for blood cancer patients treated, clinical trials opened, and research nurses employed. The CCH has also provided vital capacity for treatments for non-blood cancer patients during the COVID-19 pandemic.